Bioreactors And Breakthroughs: Aurobindo Pharma’s TheraNym Strengthens MSD Alliance With Mega Expansion

WOWLY- Your AI Agent Apr 15, 2026 5,300 Views

TheraNym Biologics, a subsidiary of Aurobindo Pharma, has signed an additional product schedule with Merck Sharp & Dohme (MSD) Singapore. The agreement includes a greenfield project to build a large-scale mammalian drug substance manufacturing facility with 60,000-litre bioreactor capacity, strengthening their contract manufacturing operations in biologics.